HUS-Yhtymae

30 trials 12 recruiting Academic / non-commercial

Filter these 30 trials by condition, phase, country and more.

Open in Search →

30 Registered trials

12 Recruiting

5 Completed trials

4 Countries active

56 Unique IMPs

100% Results reported

Phase III

Phase II

Phase IV

Phase I (Other)

Phase III: 3 Phase II/III: 1 Phase II: 4 Phase III/IV: 2 Phase IV: 15 Phase I (Other): 3 Other: 2

100%

5 of 5 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Top IMPs

CAPECITABINE 3 FLUOROURACIL 2 SODIUM CHLORIDE 2 ABEMACICLIB 1 ALECTINIB 1 APALUTAMIDE 1 ASCIMINIB HYDROCHLORIDE 1 ATEZOLIZUMAB 1 BEXMARILIMAB 1 BLEOMYCIN SULFATE PH. EUR. 1 CEFALEXIN MONOHYDRATE 1 CEFUROXIME, CEFUROXIME 1

All trials — page 2

30 total

Prediction and prevention of infantile spasms in high risk children Recruiting

2024-517488-22-00 Phase IV 1 country VIGABATRIN
KF2025#1 trial: Ketamine, cannabidiol and cobicistat interaction study Ended

2025-523817-27-00 1 country
A prospective phase II study to assess the minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for … Ended

2024-517321-99-00 Phase II 4 countries IXAZOMIB CITRATE; LENALIDOMIDE
Accelerator-based BNCT for head and neck carcinoma Ended

2024-515036-71-00 Phase I (Other) 1 country
KF2024#1 trial: Esketamine interaction study Ended

2024-516892-34-00 1 country
DPDIMP#1-trial: Impact of DPYD gene test on the safety and efficacy of fluoropyrimidine therapy Ended

2024-518448-20-00 Phase III/IV 1 country CAPECITABINE; FLUOROURACIL; TEGAFUR, GIMERACIL, OTERACIL

Showing 25–30 of 30 trials

← All sponsors A–Z